Bristol Myers says breast cancer drug IZA-BREN reduces progression or death risk by 59% in phase 3 study
BMY•Bristol Myers said IZA-BREN reduced the risk of disease progression or death by 59% versus chemotherapy in a phase 3 study of patients with advanced HR+/HER2- breast cancer. Median progression-free survival was 8.2 months with IZA-BREN and 4.0 months with chemotherapy.
1. Study results
In the phase 3 PANKU-BREAST01 study, IZA-BREN reduced the risk of disease progression or death by 59% compared with chemotherapy in patients with advanced HR+/HER2- breast cancer. Median progression-free survival was 8.2 months for IZA-BREN versus 4.0 months for chemotherapy.
2. Response and safety
The objective response rate was 40.5% for IZA-BREN versus 20.2% for chemotherapy, and median duration of response was 6.9 months versus 4.2 months. Bristol Myers said the drug's safety profile was manageable and that no new safety signals were identified.
